Last update July 18, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
μελοξικάμη is Meloxicam in Greek.
Is written in other languages:μελοξικάμη belongs to this group or family:
Main tradenames from several countries containing μελοξικάμη in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 89 | % |
Molecular weight | 351 | daltons |
Protein Binding | > 99.5 | % |
VD | 0.14 - 0. 21 | l/Kg |
pKa | 4.47 | - |
Tmax | 2 - 6 | hours |
T½ | 20 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a non-steroidal anti-inflammatory (NSAID), selective inhibitor of cyclooxygenase-2 (COX-2) that is used in the treatment of rheumatoid arthritis and other rheumatic diseases. Oral administration once daily.
At latest update, relevant information on excretion into breast milk was not found.
Due to a high serum-protein-binding capacity, excretion into breast milk seems to be unlikely.
Expert authors consider the use of meloxicam to be probably safe during breastfeeding (Briggs 2015). A similar agent, piroxicam, is classified as compatible with breastfeeding by the American Academy of Pediatrics
Until more information on this drug is available, another know therapeutic alternative should be preferred, especially in cases of breastfeeding an infant younger than one month or prematures.